Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer

다국어 초록 (Multilingual Abstract)

Radium-223 dichloride is an alpha-emitting radiopharmaceutical shown to prolong survival in patients with castrate-resistant prostate cancer (CRPC) and symptomatic skeletal metastases. This report describes in two patients the acute changes in bone metastatic activity detected by F-18 choline PET/CT imaging midway during treatment with radium-223 dichloride. In addition to visual and standardized uptake value analysis, changes in the whole-body tumor burden were quantified by measuring the difference in net metabolically active tumor volume (MATV) and total lesion activity (TLA) between pre- and mid-treatment PET scans. After the third dose of radium-223 dichloride, near-total disappearance of abnormal skeletal activity was observed in one case (net MATV change from 260.7 to 0.8 cc; net TLA change from 510.7 to 2.1), while a heterogeneous tumor response was observed in the other (net MATV change from 272.2 to 241.3 cc; net TLA change from 987.1 to 779.4). Corresponding normalization and persistent elevation in serum alkaline phosphatase levels were observed in these cases, respectively.
Further research is needed to determine the predictive value of serial F-18 choline PET/CT imaging in patients receiving radium-223 dichloride for CRPC.

참고문헌 (Reference)

1 Sonpavde G, "Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy" 30 (30): 607-613, 2012

2 Kwee SA, "Prognosis related to metastatic burden measured by 18 F-fluorocholine PET/CT in castration-resistant prostate cancer" 55 (55): 905-910, 2014

3 Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)" 45 (45): 228-247, 2009

4 Balogova S, "Effect of erythropoietin on bone marrow uptake of 18 F-fluorocholine in prostate cancer : comparison with 18 F-fluoride uptake" 38 (38): 200-202, 2013

5 Price DT, "Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer" 168 (168): 273-280, 2002

6 Glunde K, "Choline metabolism in cancer : implications for diagnosis and therapy" 6 (6): 821-829, 2006

7 Parker C, "Alpha emitter radium-223 and survival in metastatic prostate cancer" 369 (369): 213-223, 2013

8 Schoder H, "2-[18 F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy" 11 (11): 4761-4769, 2005